L Zhao1, M Zhao, Q Fang. 1. Division of Pulmonary Disease, Third Teaching Hospital, Beijing Medical University, Beijing, 100083.
Abstract
OBJECTIVE: The purpose of this study was to investigate the role of aldosterone in pulmonary fibrosis and the protective effect of anti-aldosterone treatment. METHOD: Rats were divided into control, fibrosis and treatment groups; rat pulmonary fibrosis was induced by endotracheal injection of bleomycin A5 and spironolactone was given 100 mg/kg daily in drinking water to treatment group. 28 days later, plasma, bronchoalveolar lavage fluid(BALF) and tissue aldosterone concentration, as well as lung collagen levels, were determined. RESULT: Plasma aldosterone was higher in fibrosis group than that in control group(469 +/- 161 pg/ml and 319 +/- 115 pg/ml, respectively), but without significant difference (P > 0.05); spironolactone could ameliorate the extent of pulmonary fibrosis, the level of lung collagen was 25% less than that of fibrosis group (3.4 +/- 0.5 mg/g lung and 4.6 +/- 1.2 mg/g lung, respectively; q = 3.7893, P < 0.05), and the level of lung protein was 22% less (50 +/- 4 mg/g lung and 65 +/- 6 mg/g lung, respectively; P < 0.01). CONCLUSION: Spironolactone had some protective effects on pulmonary fibrosis, and aldosterone might play a role in the development of pulmonary fibrosis.
OBJECTIVE: The purpose of this study was to investigate the role of aldosterone in pulmonary fibrosis and the protective effect of anti-aldosterone treatment. METHOD:Rats were divided into control, fibrosis and treatment groups; ratpulmonary fibrosis was induced by endotracheal injection of bleomycin A5 and spironolactone was given 100 mg/kg daily in drinking water to treatment group. 28 days later, plasma, bronchoalveolar lavage fluid(BALF) and tissue aldosterone concentration, as well as lung collagen levels, were determined. RESULT: Plasma aldosterone was higher in fibrosis group than that in control group(469 +/- 161 pg/ml and 319 +/- 115 pg/ml, respectively), but without significant difference (P > 0.05); spironolactone could ameliorate the extent of pulmonary fibrosis, the level of lung collagen was 25% less than that of fibrosis group (3.4 +/- 0.5 mg/g lung and 4.6 +/- 1.2 mg/g lung, respectively; q = 3.7893, P < 0.05), and the level of lung protein was 22% less (50 +/- 4 mg/g lung and 65 +/- 6 mg/g lung, respectively; P < 0.01). CONCLUSION:Spironolactone had some protective effects on pulmonary fibrosis, and aldosterone might play a role in the development of pulmonary fibrosis.
Authors: Zudin Puthucheary; James R A Skipworth; Jai Rawal; Mike Loosemore; Ken Van Someren; Hugh E Montgomery Journal: Sports Med Date: 2011-10-01 Impact factor: 11.136